SELLAS Life Sciences (SLS) EBIT (2020 - 2023)
Historic EBIT for SELLAS Life Sciences (SLS) over the last 7 years, with Q4 2023 value amounting to -$8.2 million.
- SELLAS Life Sciences' EBIT rose 1343.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 972.82%. This contributed to the annual value of -$37.9 million for FY2023, which is 972.82% up from last year.
- Latest data reveals that SELLAS Life Sciences reported EBIT of -$8.2 million as of Q4 2023, which was up 1343.43% from -$9.4 million recorded in Q3 2023.
- In the past 5 years, SELLAS Life Sciences' EBIT registered a high of -$2.2 million during Q1 2021, and its lowest value of -$16.7 million during Q1 2022.
- Its 4-year average for EBIT is -$7.6 million, with a median of -$7.7 million in 2022.
- In the last 5 years, SELLAS Life Sciences' EBIT surged by 4475.89% in 2021 and then plummeted by 64543.43% in 2022.
- Quarter analysis of 4 years shows SELLAS Life Sciences' EBIT stood at -$4.2 million in 2020, then tumbled by 179.37% to -$11.6 million in 2021, then grew by 18.7% to -$9.4 million in 2022, then grew by 13.43% to -$8.2 million in 2023.
- Its EBIT stands at -$8.2 million for Q4 2023, versus -$9.4 million for Q3 2023 and -$9.0 million for Q2 2023.